Speed to market remains a key driver for the digitalization of long-standing paper-based processes in drug manufacturing. Bottlenecks such as manual execution and review—all associated with bloated documentation—prevent companies from aligning with the FDA’s vision for advanced manufacturing to achieve continuous improvement. Manufacturers like GlaxoSmithKline (GSK) are embracing Pharma 4.0 and paperless technologies to help bring quality medicines to patients more quickly.